Blackstone Inc
CERE

Blackstone Inc’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Blackstone Inc’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,651
Closed -$844K – 187
2024
Q2 		$844K Sell
20,651
-14,545
-41% -$606K ﹤0.01% 139
2024
Q1 		$1.49M Buy
35,196
+20,651
+142% +$867K 0.01% 127
2023
Q4 		$617K Buy
+14,545
New +$418K ﹤0.01% 127

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Blackstone Inc's CERE Position: Q3 2024 in Review

Blackstone Inc sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 20,651 shares — an estimated $844K sold.

Blackstone Inc first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $1.49M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Blackstone Inc reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Blackstone Inc sold 20,651 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $844K.
  • Blackstone Inc first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Blackstone Inc's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.49M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Blackstone Inc's 13F filing for Q3 2024, filed 14 Nov 2024.